❌

Normal view

Moving beyond monogenic disorders in clinical healthcare

Nature Biotechnology, Published online: 05 January 2026; doi:10.1038/s41587-025-02931-2

Our understanding of the genetic mechanisms underlying rare diseases has rapidly advanced over the past decade, largely because of technological innovations. Yet clinical practice still has a strong monogenic focus, leaving many individuals undiagnosed. This Comment outlines how technological advances such as long-read sequencing should be adopted to increase multivariant testing in the clinic.

Integrated experimental and AI innovations for RNA structure determination

Nature Biotechnology, Published online: 05 January 2026; doi:10.1038/s41587-025-02974-5

RNA’s dynamic nature and complex physiochemical properties make it difficult to structurally resolve. This Perspectives examines how integrating experimental and computational approaches to structure determination can address this challenge.

The ethics of multi-cancer screening

Nature Medicine, Published online: 05 January 2026; doi:10.1038/s41591-025-04111-w

Multi-cancer detection tests offer a new paradigm in cancer screening — the use of a single test to simultaneously screen for many cancers — but they raise important ethical questions for their development, evaluation and possible implementation.
  • ✇Nature Medicine
  • Silenced genomes Sofia Moutinho
    Nature Medicine, Published online: 05 January 2026; doi:10.1038/s41591-025-04161-0Projects worldwide push for more diverse genomic databases across Asia, Africa and the Americas.
     
  • ✇Nature Cancer
  • From embryos to cancer M. Angela Nieto
    Nature Cancer, Published online: 05 January 2026; doi:10.1038/s43018-025-01098-8Angela Nieto received her PhD from Universidad Autónoma in Madrid in 1987. After short postdoctoral stays in Madrid and at the Max Planck Institute for Psychiatry in Munich, she joined the National Institute for Medical Research in London in 1989 and returned to Spain in 1993 to lead a research group at the Cajal Institute. She moved to the Neurosciences Institute in Alicante in 2004 as full professor and head of dev
     

From embryos to cancer

5 January 2026 at 08:00

Nature Cancer, Published online: 05 January 2026; doi:10.1038/s43018-025-01098-8

Angela Nieto received her PhD from Universidad Autónoma in Madrid in 1987. After short postdoctoral stays in Madrid and at the Max Planck Institute for Psychiatry in Munich, she joined the National Institute for Medical Research in London in 1989 and returned to Spain in 1993 to lead a research group at the Cajal Institute. She moved to the Neurosciences Institute in Alicante in 2004 as full professor and head of developmental neurobiology. She currently leads the cell plasticity in health and disease program and coordinates the Spanish National Research Council Cancer Hub.
❌